Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Contributed by: Business Wire

Logo

Tags

Other Consumer

Health

Consumer

Women

Pharmaceutical

Biotechnology

Organon & Co.

More Like This

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Innovaderm, a Key Collaborator in Clinical and Study Development for Recently Published Phase 1 Atopic Dermatitis Study

PR Newswire associated0

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe.

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

Stapokibart Was Granted Marketing Approval From National Medical Products Administration For The Treatment Of Moderate-to-severe Atopic Dermatitis in Adults

PR Newswire associated0

Venatorx Pharmaceuticals and Menarini Group Enter Commercial Agreement for Cefepime-Taniborbactam in 96 Countries

PR Newswire associated0

Norgine strengthens rare disease portfolio with acquisition of Theravia

Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting